Delivery Order SPE2DB22D9239-SPE2DB25FDM18
- Not listed
- The Defense Logistics Agency (DLA) issued a delivery order valued at $36,458.16 to DMS Pharmaceutical Group Inc. on September 17, 2025, for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. This firm fixed-price delivery order is expected to be completed by October 8, 2025, with fulfillment to occur at the contractor's location in Park Ridge, Illinois. The award was made without set-aside designation, and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler,...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $54,687.24 to DMS Pharmaceutical Group Inc. on September 16, 2025, for the supply of Perjeta 420 mg/14 ml vials. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The ultimate completion date for this delivery is October 7, 2025, and performance will...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $63,801.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a specific supply requirement fulfilled under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The...
- The Defense Logistics Agency (DLA) awarded a $4,557.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This delivery order, issued on June 6, 2025, with an ultimate completion date of June 30, 2025, represents a tactical pharmaceutical procurement supporting military healthcare operations. The award was made without a set-aside designation,...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc. on September 22, 2025, for the supply of Perjeta 420 mg/14 mL vials totaling $27,343.62 with firm fixed pricing. This delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA valued at $499,999,999 and effective through November 2026. The award carries no set-aside designation and requires completion by October 14, 2025, with performance based in Park Ridge,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. on August 19, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, with an ultimate completion date of September 10, 2025, will be performed at the vendor's location in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits as a woman-owned small business pharmaceutical...
- The Defense Logistics Agency awarded a $31,900.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, an oncology treatment medication. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract, valued at $8,509.92, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of the oncology drug Perjeta (pertuzumab) 420 mg/14 mL vial, with an ultimate completion date of October 10, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The contract, awarded on September 15, 2025, carries a ceiling value of $27,343.62 and utilizes firm fixed-price pricing with an ultimate completion date of October 6, 2025. This delivery order was issued without a set-aside designation, enabling DMS Pharmaceutical Group to...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB25FDM18Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, valued at $9,114.54 with a firm fixed-price structure, was awarded on September 23, 2025, with an ultimate completion date of October 15, 2025. This delivery order was issued without a set-aside designation, leveraging the vendor's competitive standing as a qualified pharmaceutical supplier within the federal procurement market. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 through November 2026. The IDC enables the DLA to procure a comprehensive range of pharmaceutical products and biologics to support medical supply requirements for Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's established role as a critical supplier in the federal pharmaceutical supply chain positions the company to efficiently deliver specialty medications, including oncology treatments like Perjeta, to military health facilities and support ongoing defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.1k | 9/23/25 |